Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

425 ARTÍCULOS , VIENDO DEL 316 AL 330

Olfactory and other sensory impairments in Alzheimer disease

Murphy C.

Nat Rev Neurol. 2019 Jan;15(1):11-24. doi: 10.1038/s41582-018-0097-5.

Key Peptides and Proteins in Alzheimer's Disease

Penke B, Bogár F, Paragi G, Gera J, Fülöp L.

Curr Protein Pept Sci. 2019;20(6):577-599. doi: 10.2174/1389203720666190103123434.

Review of Current Strategies for Delivering Alzheimer's Disease Drugs across the Blood-Brain Barrier

Wong KH, Riaz MK, Xie Y, Zhang X, Liu Q, Chen H, Bian Z, Chen X, Lu A, Yang Z.

Int J Mol Sci. 2019 Jan 17;20(2):381. doi: 10.3390/ijms20020381.

The Role of Biomarkers in Alzheimer's Disease Drug Development

Cummings J.

Adv Exp Med Biol. 2019;1118:29-61. doi: 10.1007/978-3-030-05542-4_2.

European Prevention of Alzheimer's Dementia Longitudinal Cohort Study (EPAD LCS): study protocol

Solomon A, Kivipelto M, Molinuevo JL, Tom B, Ritchie CW; EPAD Consortium.

BMJ Open. 2019 Feb 19;8(12):e021017. doi: 10.1136/bmjopen-2017-021017.

The Alzheimer Precision Medicine Initiative

Hampel H, Vergallo A, Perry G, Lista S; Alzheimer Precision Medicine Initiative (APMI).

J Alzheimers Dis. 2019;68(1):1-24. doi: 10.3233/JAD-181121.

ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker

Manzine PR, Ettcheto M, Cano A, Busquets O, Marcello E, Pelucchi S, Di Luca M, Endres K, Olloquequi J, Camins A, Cominetti MR.

Biomed Pharmacother. 2019 May;113:108661. doi: 10.1016/j.biopha.2019.108661. Epub 2019 Mar 2.

[Biomarkers of Alzheimer's disease in older and oldest old patients]

Lilamand M, Cognat E, Goutagny S, Hourregue C, Hugon J, Dumurgier J, Paquet C.

Geriatr Psychol Neuropsychiatr Vieil. 2019 Mar 1;17(1):65-72. doi: 10.1684/pnv.2019.0779.

Blood-based molecular biomarkers for Alzheimer's disease

Zetterberg H, Burnham SC.

Mol Brain. 2019 Mar 28;12(1):26. doi: 10.1186/s13041-019-0448-1.

Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial

Forlenza OV, Radanovic M, Talib LL, Gattaz WF.

Br J Psychiatry. 2019 Nov;215(5):668-674. doi: 10.1192/bjp.2019.76.

Extracellular Vesicle Biomarkers Track Cognitive Changes Following Intranasal Insulin in Alzheimer's Disease

Mustapic M, Tran J, Craft S, Kapogiannis D.

J Alzheimers Dis. 2019;69(2):489-498. doi: 10.3233/JAD-180578.

Nanowired delivery of cerebrolysin with neprilysin and p-Tau antibodies induces superior neuroprotection in Alzheimer's disease

Sharma HS, Muresanu DF, Castellani RJ, Nozari A, Lafuente JV, Tian ZR, Ozkizilcik A, Manzhulo I, Mössler H, Sharma A.

Prog Brain Res. 2019;245:145-200. doi: 10.1016/bs.pbr.2019.03.009. Epub 2019 Apr 2.

Plasmalogens and Alzheimer's disease: a review

Su XQ, Wang J, Sinclair AJ.

Lipids Health Dis. 2019 Apr 16;18(1):100. doi: 10.1186/s12944-019-1044-1.

HIV and Alzheimer's disease: complex interactions of HIV-Tat with amyloid β peptide and Tau protein

Hategan A, Masliah E, Nath A.

J Neurovirol. 2019 Oct;25(5):648-660. doi: 10.1007/s13365-019-00736-z. Epub 2019 Apr 23.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias